Overview

CAR T-cell therapy involves the treatment of cancer by modifying a patient's T-cells in the lab so they will attack cancer cells. CAR T-cell therapy is used to treat certain blood cancers, and it is currently investigated for use in treating other cancer types. If clinical development of the CART T-cell produces the wrong T-cell subtype, patient outcome will suffer.

Manufacturing CAR-T products is time-consuming, costly, highly complicated, and provides little control of the functional potency of the product beyond that of expression of a chimeric T-cell receptor.

We are developing cell culture media for T-cell subtype control to improve clinical potency in the individual patient and reduction of variability in outcomes between patients.

The data generated by our proprietary HD-DOE™ research and development platform shows that we can control the various cell lineages without a pre-requisite T-cell receptor engagement, which allows the cell to avoid exhaustion during production because if the naïve cell population is broadly activated, it will result in a mixed population of T-cells.